ArticleFrontiers in pharmacology2026
A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a widely used antiretroviral regimen, but its real-world long-term safety profile in diverse populations remains incompletely characterized. Methods: We analyzed adverse drug signals from the FAERS database (2018-2025) with B/F/TAF as the primary suspected drug. Disproportionality analyses using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) algorithms were performed to detect safety signals. Results: A total of 6,816 case reports and 13,853 adverse events were included. The highest numbers of reports were related to "Injury, poisoning and procedural complications" (n = 1,792), followed by "General disorders and administration site conditions" (n = 1,726) and "Investigations" (n = 1,499). The System Organ Classes (SOCs) meeting all four disproportionality criteria were "Congenital, familial and genetic disorders" and "Pregnancy, puerperium and perinatal conditions." The most frequently reported preferred terms were weight increase (408 cases), product dose omission (242 cases), and maternal exposure during pregnancy (202 cases), while the strongest signals by ROR were viral load increased (ROR 160.14), CD4 lymphocytes decreased (ROR 124.60), and immune reconstitution inflammatory syndrome (ROR 88.12). Overall, 37.94% of events occurred within the first month of treatment, and 17.49% occurred after one year. Conclusion: These pharmacovigilance signals merit clinical awareness, particularly regarding metabolic monitoring, virologic/immunologic parameters (which likely reflect treatment response rather than drug toxicity), and pregnancy exposure reporting. Events occurred both early and late, reinforcing the necessity of longitudinal pharmacovigilance for this widely used antiretroviral regimen. However, these findings are exploratory and should not be interpreted as confirmed causal associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.